Although B-ALL cells with GR phospho-acceptor mutations S203A or S226A are more sensitive to glucocorticoids, both retain overall synergy (S203A) or synergy with idelalisib at certain concentrations (S203A, S226A). Here, NR3C1 is linked to acute lymphoblastic leukemia.